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ABSTRACT
Objective The aim of this study was to investigate the 
association between oral anticoagulant type (direct oral 
anticoagulants (DOACs) vs vitamin K antagonists (VKAs)) 
and incident dementia or mild cognitive impairment 
(MCI) among patients with newly diagnosed atrial 
fibrillation (AF).
Methods Using linked electronic health record (EHR) 
data from the Clinical Practice Research Datalink in the 
UK, we conducted a historical cohort study among first- 
time oral anticoagulant users with incident non- valvular 
AF diagnosed from 2012 to 2018. We compared the 
incidence of (1) clinically coded dementia and (2) MCI 
between patients prescribed VKAs and DOACs using 
Cox proportional hazards regression models, with age as 
the underlying timescale, accounting for calendar time 
and time on treatment, sociodemographic and lifestyle 
factors, clinical comorbidities and medications.
Results Of 39 200 first- time oral anticoagulant users 
(44.6% female, median age 76 years, IQR 68–83), 
20 687 (53%) were prescribed a VKA and 18 513 (47%) 
a DOAC at baseline. Overall, 1258 patients (3.2%) had 
GP- recorded incident dementia, incidence rate 16.5 
per 1000 person- years. DOAC treatment for AF was 
associated with a 16% reduction in dementia diagnosis 
compared with VKA treatment in the whole cohort 
(adjusted HR 0.84, 95% CI: 0.73 to 0.98) and with 
a 26% reduction in incident MCI (adjusted HR 0.74, 
95% CI: 0.65 to 0.84). Findings were similar across 
various sensitivity analyses.
Conclusions Incident EHR- recorded dementia and MCI 
were less common among patients prescribed DOACs for 
new AF compared with those prescribed VKAs.
INTRODUCTION
Atrial fibrillation (AF) is common among older 
people, with lifetime risk estimated at around 37% 
for people aged 55 years and over.1 AF is associated 
with adverse cardiovascular outcomes including a 
five- fold increase in stroke risk2 as well as incident 
heart failure, ischaemic heart disease and peripheral 
vascular disease.3 Dementia risk is approximately 
doubled among patients with AF3–5 and remains 
elevated by around 40% among individuals with 
no history of stroke. Putative mechanisms through 
which AF may influence dementia development are 
multifactorial and include ischaemic stroke or silent 
cerebral infarction, accumulation of microemboli, 
cerebral haemorrhage and systemic inflammation.6 7
Prophylactic oral anticoagulant (OAC) treat-
ment is widely recommended to prevent stroke and 
systemic embolism in high- risk individuals with 
AF.8 A protective effect against various dementia 
subtypes is also plausible, given that cerebral 
hypoperfusion is intimately linked with neurode-
generation.9 A recent systematic review and meta- 
analysis of prospective studies (one RCT and five 
observational studies) showed a protective effect 
of OAC use compared with no OAC use against 
incident dementia in individuals with AF (RR 0.79 
(95% C.I. 0.67 to 0.93)).10 Another study showed 
similar, though slightly attenuated, beneficial effects 
of OACs against a combined dementia and cogni-
tive impairment outcome.11 For vitamin K antag-
onists (VKAs) such as warfarin, greater cognitive 
benefits were also seen with more time spent in 
therapeutic range. However, it was unclear whether 
different anticoagulant classes offered differing 
levels of cognitive protection. We hypothesised 
that direct oral anticoagulants (DOACs) such as 
apixaban may be more effective against incident 
dementia than VKAs due to better prevention 
of emboli, microvascular damage and strokes.12 
However, existing evidence for such an effect is 
limited, especially among older populations with 
multiple comorbidities.
With the rising global burden of dementia due to 
population growth and ageing, and lack of effec-
tive treatments, dementia prevention is increas-
ingly important. Understanding how, when and in 
whom to modify risk factors such as AF will inform 
dementia prevention strategies. We therefore aimed 
to investigate the association between DOACs or 
VKAs and incident dementia diagnoses in older 
patients newly diagnosed with AF using a longitu-
dinal population- based cohort derived from linked 
primary and hospital care records from the UK.
METHODS
Data sources
We used electronic health records (EHRs) from the 
UK Clinical Practice Research Datalink (CPRD) 
linked to Hospital Episodes Statistics (HES) and 
Index of Multiple Deprivation (IMD) data. CPRD 
Gold contains anonymised primary care records on 
diagnoses, tests, referrals, prescriptions and lifestyle 
factors collected during routine clinical care from 
practices using Vision software. Covering approx-
imately 7% of the UK population, it is broadly 
representative in terms of age, sex and ethnicity.13 
Around 80% of practices in England are linked to 
HES data, which comprise ICD- 10 coded records 
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1997. IMD data include area- based quintiles of deprivation 
based on patient or practice postcodes.
Study design and population
We conducted a historical cohort study among individuals with 
an incident diagnosis of non- valvular AF at age 40 years or 
more, recorded in CPRD or HES between 01 January 2012 to 
31 December 2018, with at least 12 months of research- standard 
CPRD registration. A visual presentation of the study design is 
shown in online supplemental figure 1. Patients were excluded 
if they had a history of dementia (mild cognitive impairment 
(MCI) for secondary analysis) or OAC prescription prior to AF 
(to prevent historical recording of anticoagulant use for other 
reasons). Patients with AF were identified in CPRD using Read 
codes and in HES using ICD- 10 codes.
Follow-up
Participants were followed from first OAC prescription until the 
earliest of: dementia diagnosis (MCI diagnosis for secondary 
analysis), death, transfer out of the general practice, last data 
collection date from the practice, end of OAC prescription or 
the end of study period (31 December 2018). For DOAC users, 
end of anticoagulant prescription was defined as last prescription 
date plus total days ‘on treatment’ (calculated using prescribed 
quantities and dosage information) plus an additional 30 days. 
For VKA (which has no fixed dose), we assumed that all days 
between two subsequent prescriptions were days on treatment, 
unless the gap between prescription dates exceeded 6 months or 
if there were no more prescriptions. In these cases, treatment 
was assumed to have stopped after 3 months.
Definition of exposure and outcomes
Exposure (OAC type) was defined as the first record of OAC 
prescription, identified using product codes in primary care 
records and categorised into VKAs (warfarin, phenprocoumon, 
acenocoumarol) and DOACs (dabigatran etexilate, apixaban, 
rivaroxaban). Edoxaban was not included as it was licensed in 
the UK at the end of 2015 and is not currently included in NICE 
guidance for anticoagulation in AF, so the sample size would be 
small. We time- updated the exposure so that individuals who 
switched OAC type contributed exposed time initially to one 
class and then to the other.
Among VKA users, we also explored the role of time in ther-
apeutic range (TTR) as a secondary exposure. Therapeutic 
range was defined as having an international normalised ratio 
(INR) between 2 and 3. INRs carried out during the initialisa-
tion period (within 30 days of first warfarin prescription) were 
excluded. After setting time zero as day 31 and, using INR values 
from months 1 to 6, the percentage of TTR was calculated using 
the Rosendaal method.14 Patients were classified as having ‘good 
control’ (TTR >70%), ‘intermediate control’ (TTR 50%–70%) 
and ‘poor control’ (TTR <50%).
The primary outcome was incident all- cause dementia, 
defined using Read codes for first clinical diagnosis of dementia 
in primary care records. In sensitivity analyses, we first expanded 
the outcome definition to include GP- recorded administrative 
codes as well as clinical codes to maximise sensitivity. Second, 
we restricted the sample to patients with linked secondary care 
data, which expanded the outcome to include incident dementia 
recorded in GP or hospital records. Third, to reduce the risk of 
reverse causality, we revised the outcome definition to include 
dementia occurring at least 1 year after first OAC prescription. 
Our secondary outcome was incident MCI, defined using clinical 
Read codes from primary care records.
Covariates
The following demographic and lifestyle factors were also 
included (using data closest to first OAC prescription, where 
appropriate): sex (male/female), ethnicity (Black, White, South 
Asian, Mixed/Other) body mass index—calculated from height 
and weight if available, or as entered directly, practice level 
IMD in quintiles (quintile 1 being the least deprived), smoking 
status (current/non/ex- smoker), hazardous alcohol consumption 
(binary; identified using Read codes) and primary care consul-
tation frequency in the year prior to first OAC prescription. We 
included the following clinical conditions recorded any time 
prior to OAC prescription: diabetes, hypertension, myocardial 
infarction, heart failure, stroke/thromboembolism, vascular 
disease, chronic renal disease and chronic liver disease. Other 
potential confounders, based on previous studies, included the 
following medications (recorded within 1 year prior to OAC 
prescription): statins, antiplatelet drugs or non- steroidal anti- 
inflammatory drugs, angiotensin- converting enzyme (ACE) 
inhibitor or angiotensin recepter blockers (ARB), beta- blockers, 
class 1 or 3 antiarrhythmics, digoxin, antipsychotics, antidepres-
sants and proton pump inhibitors.
Codelists for all variables in the study are available on 
LSHTM Data Compass (DOI: https:// doi. org/ 10. 17037/ DATA. 
00002326).
Statistical analysis
Baseline characteristics were described by anticoagulant class 
(VKAs vs DOACS) for first OAC prescription. We also compared 
characteristics of patients who switched OAC type with those 
who did not. Crude incidence rates of dementia were calcu-
lated overall and separately for DOACs and VKAs. We gener-
ated cumulative incidence curves using the cumulative incidence 
function to describe dementia incidence over time by OAC 
group. Cox proportional hazards regression based on the cause- 
specific hazard was then used to calculate HRs for dementia 
among DOAC versus VKAs users, with deaths from competing 
risks censored.15 Age was used as the underlying timescale in 
the models to account for strong association between age and 
dementia.16 Stata’s ‘stsplit’ command was used to split records 
at time on OAC treatment (0–6, 6–12, 12–18, 18–24, 24–36, 
36–48 and 48 plus months) and calendar year. First, we adjusted 
for age (as the time scale), calendar year, time on treatment and 
sex. We then added in socioeconomic/lifestyle factors, clinical 
conditions and medications in blocks. Results are presented for 
the final model adjusting for all co- variates, using complete case 
analysis.
Sensitivity analyses included (1) expanding the definition 
of dementia to include first clinical or administrative code for 
dementia, (2) repeating the analyses restricted to patients with 
linked primary care and hospital data, (3) only including dementia 
outcomes that occurred at least 1 year after first OAC prescrip-
tion. In a secondary analysis, we also investigated the effect of 
OAC type on incident MCI. Finally, we conducted further anal-
ysis of the VKA sample to explore any association between TTR 
and incident dementia. All analyses were performed using Stata 
MP V.16 (StataCorp LP).
RESULTS
The study population comprised 39 200 individuals with incident 
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were prescribed VKAs and 47% (N=18 513) DOACS at base-
line, with 11% (N=4477) switching OACs during the study 
period (91% from VKAs to DOACs). Figure 1 shows the steps 
taken to identify eligible study participants and the final sample 
for this study.
Overall, 44.6% of the sample were female, with a median 
age of 76 years (IQR 68–83) and a median follow- up of 501 
days (IQR 199–978). DOAC and VKA users were similar 
with respect to demographic and lifestyle factors, and there 
was no difference in the history of stroke, a major risk factor 
for dementia, between both groups. Nevertheless, patients 
prescribed VKAs generally had more comorbidities than those 
prescribed DOACs, particularly heart failure, other vascular 
disease and chronic renal disease. While patients prescribed 
DOACs were less likely to be using antiplatelet drugs (58.7% vs 
68.7%), diuretics (43.5% vs 49.5%) and ACE inhibitors (37.8% 
vs 42.6%) compared with those prescribed VKAs at baseline, 
they had a greater use of beta- blockers (69.2% vs 66.0%), 
antidepressants (19.1% vs 17.7%) and proton pump inhibi-
tors (46.7% vs 44.6%). Baseline characteristics of the sample 
by OAC type are shown in table 1. OAC treatment initiation 
patterns can be found in online supplemental figure 2. Charac-
teristics of the 11% who switched OAC type during the study 
are shown in online supplemental table 1.
Incidence rates of dementia and mild cognitive impairment
During follow- up, 1258 patients (3.2%) received a first- time 
diagnosis of GP- recorded dementia. The overall crude rate of 
all- cause dementia was 16.5 per 1000 person- years. The rate was 
slightly lower among patients prescribed DOACs compared with 
those prescribed VKAs (figure 2) and increased with age for both 
treatment groups (online supplemental figure 3). Overall, 1488 
patients (4.0%) received a diagnosis of MCI, with a crude rate 
of 20.05 per 1000 person- years, which was lower among those 
prescribed DOACs (figure 2).
Figure 1 Flowchart of study participants. AF, atrial fibrillation; CPRD, 
Clinical Practice Research Datalink; DOACs, direct oral anticoagulants; 
HES, Hospital Episodes Statistics; VKA, vitamin K antagonists.







Male 11 444 (55.3) 10 267 (55.5)
Female 9243 (44.7) 8246 (44.5)
Age category, years
40–59 5854 (28.3) 5461 (29.5)
60–69 7821 (37.8) 6367 (34.4)
70–79 7012 (33.9) 6685 (36.1)
Ethnicity
White 9930 (48.0) 8617 (46.5)
South Asian 122 (0.6) 82 (0.4)
Black 56 (0.3) 52 (0.3)
Mixed/other 92 (0.4) 65 (0.4)
Missing 10 487 (50.7) 9697 (52.4)
Socioeconomic status (IMD—patient level)
1 2515 (12.2) 2395 (12.9)
2 2473 (12.0) 1881 (10.2)
3 2262 (10.9) 1738 (9.4)
4 1765 (8.5) 1278 (6.9)
5 1343 (6.5) 1051 (5.7)
Missing 10 329 (49.9) 10 170 (54.9)
Socioeconomic status (IMD—practice level)
1 3774 (18.2) 3672 (19.8)
2 3337 (16.1) 2983 (16.1)
3 4622 (22.3) 4055 (21.9)
4 4242 (20.5) 3428 (18.5)
5 4712 (22.8) 4375 (23.6)
BMI category
Underweight 418 (2.0) 414 (2.2)
Normal 5056 (24.4) 4727 (25.5)
Overweight 8372 (40.5) 7396 (40.0)
Obese 6841 (33.1) 5976 (32.3)
Hazardous alcohol status
Yes 1245 (6.0) 1486 (8.0)
No 19 442 (94.0) 17 027 (92.0)
Smoking status
Non/ex- smoker 18 679 (90.3) 16 419 (88.7)
Current 1981 (9.6) 2034 (11.0)
Missing 27 (0.1) 60 (0.3)
Consultation frequency/year
1 to 10 2024 (12.2) 3393 (15.0)
11 to 20 5208 (31.4) 7075 (31.3)
21 to 30 4319 (26.0) 5342 (23.7)
31 to 40 2429 (14.6) 3084 (13.6)
41 to 50 1217 (7.3) 1658 (7.3)
51 to 60 588 (3.5) 838 (3.7)
Over 60 738 (4.4) 1155 (5.1)
None 92 (0.6) 40 (0.2)
Calendar year of OAC prescription
2012 3975 (23.9) 170 (0.8)
2013 4456 (26.8) 1116 (4.9)
2014 3793 (22.8) 2618 (11.6)
2015 2401 (14.5) 4606 (20.4)
2016 1159 (7.0) 4839 (21.4)
2017 547 (3.3) 4805 (21.3)
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DOACs versus VKAs and associations with dementia or MCI
Treatment of AF with a DOAC was associated with a 16% reduc-
tion in incident dementia diagnosis than treatment with a VKA 
(HR 0.84, 95% CI: 0.73 to 0.98), after adjusting for all covari-
ates. DOACs were also found to be associated with a 26% reduc-
tion in MCI compared with VKAs (HR 0.74, 95% CI: 0.65 to 
0.84). Age, sex and time- adjusted, and fully adjusted estimates 
are shown in figure 2. Partially and fully adjusted models are 
shown in detail in online supplemental table 2.
Sensitivity analyses
Sensitivity analyses are shown in table 2. Results were similar 
when expanding the definition of dementia to first clin-
ical or administrative code recorded in primary care records 
(N=39 028; HR 0.85, 95% CI: 0.72 to 1.01), although they 
just failed to reach statistical significance. A protective associa-
tion was also seen when restricting the sample to patients with 
linked primary care and hospital records (N=18 080; HR 0.77, 
95% CI: 0.60 to 0.99) and when only including dementia that 
occurred at least 1 year after first OAC prescription (N=39 200; 
HR 0.81, 95% CI: 0.67 to 0.98).
Time in therapeutic range and incident dementia among VKA 
users
Among 12 856 VKA users with at least three INRs measured 
in months 1–6 (median number of INRs 12, IQR 9–15), 48% 
(N=6186) demonstrated good control (TTR >70%), 30.3% 
(N=3905) intermediate control (TTR 50%–70%) and 21.7% 
(N=2789) poor control (TTR <50%). Good INR control was 
associated with 27% reduction in incident dementia diagnosis 
(figure 3) compared with poor INR control (HR 0.73, 95% CI: 
0.57 to 0.92).
DISCUSSION
In this population- based cohort study of 39 200 individuals, 
DOAC treatment for incident AF was associated with a 16% 
reduction in new diagnoses of all- cause dementia compared with 
treatment with VKAs. The magnitude and direction of effect esti-
mates were consistent across sensitivity analyses. DOACs were 
also associated with a 26% reduction in incident MCI diagnoses.
Our results are consistent with studies suggesting favourable 
outcomes of DOACs compared with VKAs against composite 
vascular endpoints including dementia. A propensity score- 
matched cohort study of 5254 OAC users with AF from the 
USA showed that DOACs were associated with a reduction in 
stroke, transient ischaemic attack or dementia compared with 
warfarin use (HR 0.49, 95% CI 0.35 to 0.69).17 A large Swedish 
study comparing the effect of DOACs vs warfarin on ischaemic 
or haemorrhagic stroke or dementia among low- risk individuals 






Diabetes status 5538 (26.8) 4548 (24.6)
Hypertension history 14 317 (69.2) 12 403 (67.0)
Myocardial infarction history 2541 (12.3) 2071 (11.2)
Heart failure history 5225 (25.3) 3843 (20.8)
Stroke/transient ishemic attack/thromboembolism 
history
3776 (18.3) 3438 (18.6)
Vascular disease history 6002 (29.0) 4775 (25.8)
Renal disease history 6672 (32.3) 5235 (28.3)
Liver disease history 399 (1.9) 441 (2.4)
Medications at baseline
Statin use 14 459 (69.9) 12 570 (67.9)
Antiplatelet drugs/NSAIDs 14 210 (68.7) 10 868 (58.7)
ACE inhibitors or ARBs 8806 (42.6) 7000 (37.8)
Beta- blockers 13 651 (66.0) 12 815 (69.2)
Class I or III antiarrhythmics 1461 (7.1) 1065 (5.8)
Digoxin 2524 (12.2) 1914 (10.3)
Diuretics 10 230 (49.5) 8045 (43.5)
Antidepressant medications 3667 (17.7) 3534 (19.1)
Antipsychotic medications 113 (0.5) 150 (0.8)
Proton pump inhibitors 9226 (44.6) 8644 (46.7)
ACE, angiotensin- converting enzyme ; ARBs, angiotensin receptor blockers; 
BMI, body mass index; DOAC, direct oral anticoagulant; IMD, Index of Multiple 
Deprivation; NSAIDs, non- steroidal anti- inflammatory drugs ; OAC, oral 
anticoagulant; VKA, vitamin K antagonist.
Table 1 Continued
Figure 2 Association between oral anticoagulant use and incident dementia and mild cognitive impairment, defined using clinical codes. ˆAdjusted 
for age, calendar year, time- on- treatment and sex. *Adjusted for age, calendar year, time- on- treatment, sex, body mass index, smoking status, 
hazardous alcohol consumption, socio economic status (practice level Index of Multiple Deprivation), primary care consultation frequency, diabetes, 
hypertension, myocardial infarction, statins, heart failure, stroke, vascular disease, renal disease, liver disease, antiplatelet drugs, ACE/ARB inhibitors, 
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(HR 0.47, 95% CI 0.18 to 1.22).18 Although an earlier cohort 
study from Sweden showed no difference in dementia associ-
ated with DOACs compared with warfarin (HR 0.97, 95% CI 
0.67 to 1.40), the study ended in 2014 and only 2.9% of the 
study population received a DOAC.19 While a recent study using 
UK primary care data found no significant difference in inci-
dent dementia or cognitive impairment in DOAC users versus 
warfarin (HR 0.89 95% CIs 0.70 to 1.14),11 as in our study, the 
direction of HRs favoured DOACs.
Prophylactic oral anticoagulation is recommended to prevent 
stroke among high- risk individuals with AF after taking bleeding 
risk into account.8 A systematic review and meta- analysis of 
trial data showed a 19% reduction in risk of stroke or systemic 
embolic events among participants receiving DOACs compared 
with warfarin.20 Similar results were seen in a large observational 
study using US claims data.21 While the protective association of 
DOACs that we showed against diagnosed dementia was smaller 
than effects identified in other studies, these may have been 
driven by the notable effectiveness of DOACs against stroke. 
Mechanisms to explain the link between AF and dementia 
include stroke, silent cerebral infarction and microemboli, as well 
as indirect effects of cerebrovascular hypoperfusion on oxidative 
stress, inflammation and blood–brain barrier disruption, which 
contribute to progression of both vascular dementia and Alzhei-
mer’s disease.22–24
Strengths and limitations
This is the first study using representative data from a real- world 
UK population to investigate the association between OAC type 
and dementia diagnosis. In contrast to other studies comparing 
the effect of OAC with no OAC, we used an active comparator 
new user design to reduce both confounding by indication and 
biases such as healthy user bias.25 In the UK, OACs for stroke 
prevention are not recommended to patients with AF aged under 
65 years with low stroke risk (equating to CHA2DS2VASc score 
of 0 for men or 1 for women).8 We therefore did not include 
individuals without OACs who would have markedly lower 
stroke and dementia risk. In our sample, data on sociodemo-
graphic and lifestyle factors (excluding ethnicity) were >99% 
complete, enabling complete case analysis with negligible risk of 
bias. We carried out several sensitivity analyses to test the robust-
ness of our assumptions.
There were however some limitations. While the positive predic-
tive value of a dementia diagnosis in EHR data is over 80%,26 only 
two- thirds of people with dementia in the UK have their diagnosis 
Table 2 Association between oral anticoagulant use and incident dementia, in a series of sensitivity analysis
No of events
Total person- time 
(person- years)
Crude rate (per 1000 
years)
Adjusted for age, calendar time, time on 
treatment and sex Fully adjusted model*
HR (95% CI) P value HR (95% CI) P value
(A) Dementia defined using clinical or administrative codes (N=39 028)*
  VKA 568 45 570 12.46 (11.48 to 13.53) 1.00 1.00
  DOAC 353 32 101 11.00 (9.91 to 12.21) 0.94 (0.79 to 1.11) 0.46 0.85 (0.72 to 1.01) 0.07
(B) Among patients with linked GP and hospital records (N=18 080)†
  VKA 319 19 205 16.61 (14.88 to 18.54) 1.00 1.00
  DOAC 173 12 907 13.40 (11.55 to 15.56) 0.84 (0.66 to 1.09) 0.19 0.77 (0.60 to 0.99) 0.04
(C) Dementia occurring at least 1 year after first oral anticoagulant prescription (N=39 200)*
  VKA 502 45 593 11.01 (10.09 to 12.02) 1.00 1.00
  DOAC 234 32 321 7.23 (6.37 to 8.23) 0.88 (0.73 to 1.07) 0.20 0.81 (0.67 to 0.98) 0.03
*Adjusted for calendar year, time- on- treatment, sex, body mass index, smoking status, hazardous alcohol consumption, socioeconomic status (practice level IMD), primary care 
consultation frequency, diabetes, hypertension, myocardial infarction, statins, heart failure, stroke, vascular disease, renal disease, liver disease, antiplatelet drugs, ACE/ARB 
inhibitors, beta- blockers, antiarrhythmics, digoxin, diuretics, antipsychotics, antidepressants and proton pump inhibitors.
†Adjusted for same covariates as above, except for socioeconomic status—patient- level IMD used for this model.
DOAC, direct oral anticoagulant; IMD, Index of Multiple Deprivation.
Figure 3 Association between time in therapeutic range (TTR) and risk of dementia among warfarin users (N=12 856). ˆAdjusted for age, calendar 
year, time- on- treatment and sex. *Adjusted for age, calendar year, time- on- treatment, sex, body mass index, smoking status, hazardous alcohol 
consumption, socio economic status (practice level Index of Multiple Deprivation), primary care consultation frequency, diabetes, hypertension, 
myocardial infarction, statins, heart failure, stroke, vascular disease, renal disease, liver disease, antiplatelet drugs, ACE/ARB inhibitors, beta- blockers, 
antiarrhythmics, digoxin, diuretics, antipsychotics, antidepressants and proton pump inhibitors. Note: <50% TTR = poor INR control, 50–70 TTR = 
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recorded.27 The onset of dementia may lead to some individuals 
entering residential care. Although CPRD practices cover residen-
tial and nursing homes, some individuals may transfer to GP prac-
tices not included in CPRD for example, to be near family, which 
would result in missed diagnoses. As recording of dementia diag-
nosis may be more common among those who consult frequently, 
we adjusted for habitual consultation frequency. While warfarin 
users additionally require regular INR monitoring, all patients in 
our sample received regular prescriptions across the study period, 
so it is unlikely that dementia recording would differ by OAC type. 
As OAC data were obtained from prescriptions, it was not possible 
to assess medication adherence directly. A recent systematic review 
and meta- analysis suggests that one in three DOAC users has subop-
timal adherence, taking their DOAC <80% of the time.28 In that 
study, pooled persistence was higher for DOACs than for VKAs. 
Differences in adherence may partly explain our findings: subop-
timal adherence was associated with increased dementia risk among 
VKA users who spent <50% of time in the therapeutic range.
We allowed patients switch from one OAC class to another to 
reduce exposure misclassification that would have occurred increas-
ingly over time if we had based exposure on first OAC prescrip-
tion. We expected minimal carryover effects: effects of DOACs fade 
12–24 hours after last dose; while warfarin may stay in the system 
for 3–4 days after last dose. In a study of a long- term outcome such 
as dementia, there would be minimal effect on exposure misclassi-
fication. While switching from a VKA to a fixed dose medication 
may be prompted by early cognitive problems, this would bias 
results towards the null, bringing rates of dementia among DOAC 
users closer to those of VKA users. In addition, our analysis of the 
secondary outcome MCI, which precludes the presence of func-
tional impairment sufficient to prevent patients from managing a 
variable dose VKA, showed consistent results.
In common with other studies, VKA users had evidence of 
slightly more comorbidities than DOAC users,29 although history 
of stroke was similar between groups, and we controlled for a 
wide range of measured comorbidities as potential confounders. 
A previous study showed that patients with extensive cardiovas-
cular comorbidities were less likely to have a dementia diagnosis 
in their primary care record, despite meeting standardised diag-
nostic criteria.30 If this were also true in our study, it suggests 
dementia might be under- recorded in VKA users, meaning we 
have underestimated the protective effect of DOACs. We did not 
have data on some dementia risk factors, such as history of trau-
matic brain injury or family history of dementia, although these 
are unlikely to affect anticoagulant choice. In future, alternative 
causal inference methods such as propensity scores or marginal 
structural models could be explored, to control for time- varying 
confounding. Investigating mechanisms through which DOACs 
may reduce dementia risk compared with VKAs should also be a 
focus of future research.
Conclusions
We observed that individuals taking DOACs for AF were less 
likely to be diagnosed with dementia and MCI than those taking 
VKAs, after adjusting for potential confounding factors. While 
further evidence, including from randomised controlled trials, 
would strengthen this finding, it may be relevant to consider 
cognitive risk profile when prescribing OACs for AF among 
older individuals.
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Key messages
What is already known on this subject?
 ► Oral anticoagulant use in atrial fibrillation (AF) has been 
linked with a reduction in dementia incidence.
 ► While direct oral anticoagulants (DOACs) offer superior 
protection against stroke and systemic embolism compared 
with vitamin K antagonists (VKAs) in randomised controlled 
trials (RCTs), it is unclear whether levels of cognitive 
protection differ by anticoagulant type.
What might this study add?
 ► We compared incident dementia diagnoses among 
individuals with new onset AF who were receiving either 
DOACs or VKAs in a large electronic health record- based 
cohort from the UK.
 ► DOAC treatment for incident AF was associated with a 
reduction in new diagnoses of all- cause dementia and mild 
cognitive impairment compared with treatment with VKAs.
How might this impact on clinical practice?
 ► It may be relevant to consider cognitive risk profile when 
prescribing oral anticoagulants for AF to older individuals.
 ► A better understanding of mechanisms through which 
anticoagulants influence dementia risk is needed, along with 
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